These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9435043)

  • 21. Clearing Chlamydia abortus infection in epithelial cells and primary human macrophages by use of antibiotics and the MDM2-p53-inhibitor nutlin-3.
    Diensthuber D; Simnacher U; Peters S; Walther P; Essig A; Hagemann JB
    Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115715. PubMed ID: 35598409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxycycline suppresses Chlamydia pneumoniae induced interferon-gamma responses in peripheral blood mononuclear cells in children with allergic asthma.
    Smith-Norowitz TA; Weaver D; Norowitz YM; Hammerschlag MR; Joks R; Durkin HG; Kohlhoff S
    J Infect Chemother; 2018 Jun; 24(6):470-475. PubMed ID: 29615379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chlamydia pneumoniae enhances Interleukin 8 (IL-8) production with reduced azithromycin sensitivity under hypoxia.
    Matsuo J; Sakai K; Okubo T; Yamaguchi H
    APMIS; 2019 Mar; 127(3):131-138. PubMed ID: 30746791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A reverse transcriptase-PCR based assay for in-vitro antibiotic susceptibility testing of Chlamydia pneumoniae.
    Khan MA; Potter CW; Sharrard RM
    J Antimicrob Chemother; 1996 Apr; 37(4):677-85. PubMed ID: 8722533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and the duration of the presence of antibiotics.
    Notomi T; Ikeda Y; Nagayama A
    Chemotherapy; 1999; 45(4):242-8. PubMed ID: 10394006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
    Hammerschlag MR; Roblin PM
    J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
    [No Abstract]   [Full Text] [Related]  

  • 27. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
    Riska PF; Kutlin A; Ajiboye P; Cua A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Koetsveld J; Draga ROP; Wagemakers A; Manger A; Oei A; Visser CE; Hovius JW
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Antimicrob Chemother; 2003 Sep; 52(3):497-9. PubMed ID: 12917246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
    Baradaran-Dilmaghani R; Stanek G
    Infection; 1996; 24(1):60-3. PubMed ID: 8852472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection.
    Beale AS; Masson ND
    J Antimicrob Chemother; 1994 Dec; 34(6):1072-4. PubMed ID: 7730224
    [No Abstract]   [Full Text] [Related]  

  • 32. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
    Samra Z; Rosenberg S; Dan M
    J Chemother; 2011 Apr; 23(2):77-9. PubMed ID: 21571622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.
    Waites KB; Crabb DM; Duffy LB; Jensen JS; Liu Y; Paukner S
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Niki Y; Matsushima T
    J Antimicrob Chemother; 2001 Sep; 48(3):403-5. PubMed ID: 11533006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India.
    Bhengraj AR; Vardhan H; Srivastava P; Salhan S; Mittal A
    Chemotherapy; 2010; 56(5):371-7. PubMed ID: 20938174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New real-time PCR-based method for in vitro susceptibility testing of Anaplasma phagocytophilum against antimicrobial agents.
    Hunfeld KP; Bittner T; Rödel R; Brade V; Cinatl J
    Int J Antimicrob Agents; 2004 Jun; 23(6):563-71. PubMed ID: 15194126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1998 Jan; 42(1):194-6. PubMed ID: 9449287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
    Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR
    APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae.
    Bouwman JJ; Visseren FL; Bouter PK; Diepersloot RJ
    J Lab Clin Med; 2004 Jul; 144(1):18-26. PubMed ID: 15252403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Azithromycin decreases Chlamydia pneumoniae-mediated Interleukin-4 responses but not Immunoglobulin E responses.
    Smith-Norowitz TA; Huang Y; Loeffler J; Klein E; Norowitz YM; Hammerschlag MR; Joks R; Kohlhoff S
    PLoS One; 2020; 15(6):e0234413. PubMed ID: 32511255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.